

1 Emergence and rising of ceftazidime-avibactam resistant KPC-producing

2 *Pseudomonas aeruginosa* in China: a molecular epidemiology study

3 Yiwei Zhu<sup>1,2,3</sup>, Jie Chen<sup>1,2,3,a</sup>, Han Shen<sup>4</sup>, Zhongju Chen<sup>5</sup>, Qi-wen Yang<sup>6</sup>,

4 Jin Zhu<sup>7</sup>, Xi Li<sup>8</sup>, Qing Yang<sup>9</sup>, Feng Zhao<sup>10</sup>, Jingshu Ji<sup>10</sup>, Heng Cai<sup>1,2,3</sup>, Yue

5 Li<sup>1,2,3</sup>, Linghong Zhang<sup>1,2,3</sup>, Sebastian Leptihn<sup>11</sup>, Xiaoting Hua<sup>1,2,3</sup>,

6 Yunsong Yu<sup>1,2,3</sup>

7 <sup>1</sup>Department of Infectious Diseases, Sir Run Run Shaw Hospital,

8 Zhejiang University School of Medicine, Hangzhou, China

9 <sup>2</sup>Key Laboratory of Microbial Technology and Bioinformatics of

10 Zhejiang Province, Hangzhou, China

11 <sup>3</sup>Regional Medical Center for National Institute of Respiratory Diseases,

12 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,

13 Hangzhou, China

14 <sup>4</sup>Department of Laboratory Medicine, Nanjing Drum Tower Hospital,

15 Nanjing University Medical School, Nanjing, China

16 <sup>5</sup>Department of Laboratory Medicine, Tongji Hospital, Tongji Medical

17 College, Huazhong University of Science and Technology, Wuhan, China

18 <sup>6</sup>Department of Laboratory Medicine and Beijing Key Laboratory for

19 Mechanisms Research and Precision Diagnosis of Invasive Fungal

20 Diseases, Peking Union Medical College Hospital, Chinese Academy of

21 Medical Sciences and Peking Union Medical College, Beijing, China

22 <sup>7</sup>Department of Clinical Laboratory, Quzhou People's Hospital, Affiliated

23 Quzhou Hospital of Wenzhou Medical University, Quzhou, China

24 <sup>8</sup>Centre of Laboratory Medicine, Zhejiang Provincial People's Hospital,

25 People's Hospital of Hangzhou Medical College, Hangzhou, China

26 <sup>9</sup>State Key Laboratory for Diagnosis and Treatment of Infectious

27 Diseases, Collaborative Innovation Center for Diagnosis and Treatment

28 of Infectious Diseases, The First Affiliated Hospital, College of Medicine,

29 Zhejiang University, Hangzhou, China

30 <sup>10</sup>Department of Clinical Laboratory, Sir Run Run Shaw Hospital,

31 Zhejiang University School of Medicine, Hangzhou, China

32 <sup>11</sup>The Zhejiang University-University of Edinburgh Institute, Zhejiang

33 University-Edinburgh University Institute, Zhejiang University,

34 International Campus, Haining, China; Department of Infectious Diseases,

35 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,

36 Hangzhou, China; School of Medicine, Edinburgh University, Edinburgh,

37 UK

38 <sup>a</sup>Present address: Department of Laboratory, Ningbo Medical Center

39 Lihuili Hospital, Ningbo, China

40 Correspondence:

41 Xiaoting Hua address: No. 3, East Qingchun Rd, Jianggan District,

42 Hangzhou, China, 310016 [xiaotinghua@zju.edu.cn]

43 Yunsong Yu address: No. 3, East Qingchun Rd, Jianggan District,

44 Hangzhou, China, 310016 [yvys119@zju.edu.cn]

45 **Background:** Infections by Carbapenem-resistant *Pseudomonas*  
46 *aeruginosa* (CRPA) are difficult to treat and novel antibiotics are  
47 desperately needed. Till today, ceftazidime-avibactam (CAZ-AVI) has  
48 been used to treat infections caused by multidrug resistant (MDR)  
49 Gram-negative bacteria, including *Klebsiella pneumoniae* carbapenemase  
50 (KPC)-producing organisms. Although cases of KPC-producing *P.*  
51 *aeruginosa* (KPC-PA) have been reported sporadically, data about  
52 KPC-PA susceptibility to CAZ-AVI and its molecular characteristics are  
53 limited.

54 **Methods:** CRPA were collected from seven hospitals in China from 2017  
55 to 2018. PCR was deployed to screen for the *bla*<sub>KPC</sub> gene. Antimicrobial  
56 susceptibility of KPC-PA was determined by broth microdilution method  
57 or agar dilution method. We combined Illumina sequencing and  
58 Nanopore long-read sequencing to elucidate the genomic characteristics  
59 of KPC-PA strains.

60 **Results:** KPC-PA strains were found in six out of seven hospitals.  
61 151/374 (40.4%) CRPA clinical isolates harbored the *bla*<sub>KPC-2</sub> gene.  
62 Among KPC-PA, ST463 (107/151) was predominant, followed by ST485  
63 (14/151) and ST1212 (12/151). Approximately half of all KPC-PA  
64 (50.3%) were susceptible to CAZ-AVI. We found that the *bla*<sub>KPC-2</sub> gene  
65 copy number correlated with CAZ-AVI MIC. In more than 90% (136/151)  
66 of the strains, we found plasmids that belonged to two types carrying

67 *bla*<sub>KPC-2</sub> gene. The Type 1 plasmid, predominant in East China, was  
68 identified in 118 strains and the Type 2 plasmid, belonged to a  
69 megaplasmid family spreading globally, was identified in 19 strains. In  
70 addition, we identified IS26- $\Delta$ Tn6296 and IS6100- $\Delta$ Tn6296-Tn1403 as  
71 two mobile genetic elements that mediated *bla*<sub>KPC-2</sub> gene transmission.

72 **Conclusion:** Our results suggest that the *bla*<sub>KPC-2</sub> gene is becoming a  
73 remarkable mediator of carbapenem resistance in *P. aeruginosa* in China.  
74 The emergence and spread of such KPC-PA strains poses a threat on  
75 clinical therapy as CAZ-AVI becomes inefficient. It would be beneficial  
76 to screen for the *bla*<sub>KPC</sub> gene in CRPA strains for antimicrobial  
77 surveillance.

78 **Keywords:** *Pseudomonas aeruginosa*, *bla*<sub>KPC-2</sub>, ceftazidime-avibactam

79

80 **Background**

81 *Pseudomonas aeruginosa*, one of major opportunistic pathogens, is  
82 notorious for its potency to resist antibiotics including carbapenems.  
83 Although carbapenems are still among the first-line therapeutics for  
84 infections caused by multi-drug resistant (MDR) *P. aeruginosa*,  
85 carbapenem-resistant *P. aeruginosa* (CRPA) are increasingly observed in  
86 the clinic. Indeed, CRPA is among the pathogens listed by the World  
87 Health Organization (WHO) that are considered of high relevance for  
88 human health and for which new antibiotics or clinical strategies are



89 urgently needed [1].

90 Approved by the U.S. Food and Drug Administration (FDA) in 2015,  
91 ceftazidime-avibactam (CAZ-AVI), a novel  $\beta$ -lactam/ $\beta$ -lactamase  
92 inhibitor combination, has been deployed in the clinic for complicated  
93 intraabdominal infections and for hospital-acquired pneumonia caused by  
94 multidrug-resistant *Enterobacteriaceae* and *P. aeruginosa* [2]. The  
95 inhibition spectrum of avibactam includes the *Klebsiella pneumoniae*  
96 carbapenemase family (KPC) [3]. According to INFORM surveillance  
97 [4-6], CAZ-AVI susceptibility rates are between 84-90% to CRPA that do  
98 not express metallo- $\beta$ -lactamase (MBL). However, no study has detailed  
99 the CAZ-AVI susceptibility of KPC-PA as a single group, and  
100 investigated occurring resistance mechanisms, possibly due to the  
101 currently low prevalence of such strains. Perhaps unsurprisingly, an  
102 increasing number of *bla*<sub>KPC</sub> genes have been detected in clinical *P.*  
103 *aeruginosa* isolates over the last years [7-12]. An example is the Eastern  
104 Chinese city of Hangzhou, where the rate of KPC-PA has increased  
105 significantly since the first case was reported a decade ago [13, 14].

106 Most of the investigated *bla*<sub>KPC</sub> genes in *P. aeruginosa* have been  
107 reported to be plasmid-encoded [15-18], while a small number are found  
108 on the bacterial chromosome, occasionally in prophage sequences [12,  
109 19]. However, most of these studies are single case reports and focus on  
110 the description of the genetic structure of *bla*<sub>KPC</sub> and its surrounding

111 sequences. Therefore, the importance of KPC-PA strains and their  
112 relevance for the clinic remain unclear.

113 In this study, we analyzed the prevalence of KPC-PA strains from  
114 seven hospitals in China and tested *in vitro* antimicrobial susceptibility.  
115 We used Illumina and Nanopore sequencing technology to elucidate the  
116 molecular epidemiology and genetic characteristics of the KPC-PA  
117 strains.

118 Our data revealed that the susceptibility to CAZ-AVI of *Pseudomonas*  
119 *aeruginosa* was 50.3% in China. We found that the distribution of  
120 resistance genes was mediated by two major KPC-carrying plasmid types.  
121 Our data showed that the *bla*<sub>KPC-2</sub> gene copy number was associated with  
122 CAZ-AVI MIC.

## 123 **Methods**

### 124 **Sample collection and antimicrobial susceptibility tests**

125 Clinical CRPA isolates were collected from seven hospitals around China,  
126 including from Sir Run Run Shaw Hospital (SRRSH), the First affiliated  
127 hospital of Zhejiang University (FAHZU), Provincial People's Hospital  
128 of Zhejiang (ZPPH), Quzhou People's Hospital (QZPH), Nanjing Drum  
129 Tower Hospital (NDTH), Wuhan Tongji Hospital (WTJH) and Peking  
130 Union Medical College Hospital (PUMCH). Five hospitals were located  
131 in Eastern China (SRRSH, FAHZU, ZPPH, QZPH and NDTH), while

132 other two (WTJH, PUMCH) were in Central and Northern China,  
133 respectively. All of these samples were isolated from patients between  
134 January, 2017 to February, 2018 and sent to SRRSH for investigation.

135 The *bla*<sub>KPC</sub> gene was screened by PCR using the primers KPC-2\_FW  
136 (5'-AGGTTCCGGTTTTGTCTC-3') and KPC-2\_RV  
137 (5'-AGGTTCCGGTTTTGTCTC-3').

138 *In vitro* antibiotic susceptibility of 13 antipseudomonal antimicrobial  
139 agents was determined by broth microdilution or agar dilution method.  
140 The antibiotics included piperacillin-tazobactam, ceftazidime, cefepime,  
141 ceftazidime-avibactam, aztreonam, imipenem, meropenem, amikacin,  
142 gentamycin, tobramycin, ciprofloxacin, levofloxacin and colistin.  
143 Antimicrobial agents were prepared from commercially available sources.  
144 Breakpoints were referred to Clinical and Laboratory Standards Institute  
145 (CLSI) M100 [20]. *P. aeruginosa* strain ATCC 27853 and *K. pneumoniae*  
146 strain ATCC700603 was used as the quality control. Difficult-to-treat  
147 resistance (DTR) is defined as *P. aeruginosa* exhibiting non-susceptibility  
148 to all of the following: piperacillin-tazobactam, ceftazidime, cefepime,  
149 aztreonam, meropenem, imipenem-cilastatin, ciprofloxacin, and  
150 levofloxacin [21].

### 151 **Whole-genome sequencing**

152 For each KPC-PA strain, a single clone was inoculated into 5 mL

153 Luria-Bertani broth and incubated in a 37°C shaker overnight. Bacteria  
154 were lysed by FastPrep-24™ 5G bead beating grinder (MP Biomedicals,  
155 CA, USA) at 6.0m/sec for 40 seconds twice. Genome DNA were  
156 extracted using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)  
157 according to the manufacturer. DNA concentration was quantified using a  
158 NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA),  
159 and verified by agarose gel electrophoresis. Libraries were prepared using  
160 the TruePrep DNA Library Prep Kit V2 for Illumina (Vazyme Biotech,  
161 Nanjing, China), and sequenced on an Illumina X Ten platform (Illumina  
162 Inc., San Diego, CA, USA) and 150-bp paired end reads were generated.  
163 The Illumina sequence data were *de novo* assembled by shovill v1.1.0 [22]  
164 with options “--mincov 10 --minlen 200 --trim” and SPAdes v.3.13-v.3.14  
165 [23] as the assembler.

166 To further investigate the molecular characteristics of KPC-PA, we  
167 pursued Nanopore MinION long-read sequencing (Oxford Nanopore  
168 Technologies, Oxford, UK) on 6 isolates (SRRSH1002, SRRSH1408,  
169 NDTH10366, SRRSH15, WTJH12 and QZPH41). These isolates were  
170 selected based on their sequence type, plasmid type, *bla*<sub>KPC-2</sub> copy  
171 number and geographic distribution. Another strain, SRRSH1101,  
172 *bla*<sub>KPC-2</sub>-negative but harboring Type 1 plasmid, also underwent Nanopore  
173 sequencing to help illuminate the dynamics of multiple *bla*<sub>KPC-2</sub> copies.  
174 The raw reads of the sequenced isolates were mapped onto three

175 representative plasmid sequences (GenBank accession: KY296095.1,  
176 MN433457.1 and KU578314.1) by bwa-mem v.0.7.17 [24] to identify  
177 plasmid type. These plasmids were categorized into three types based on  
178 sequence similarity (cutoff is 50%).

## 179 **Gene synteny**

180 To attribute contigs to plasmid, genome draft of each strain was aligned  
181 to representative plasmid of each type by mummer v.4.0.0beta [25].  
182 Results were filtered with a minimum length of 1000bp. The sum length  
183 of each contigs which matched with respective representative plasmid  
184 was calculated by a custom R script. Only contigs with more than 50% of  
185 length matched with representative plasmid were attributed to plasmid  
186 contigs. These plasmid contigs were re-annotated by Prokka v.1.14.6 [26],  
187 with representative plasmid as the prior source. Orthologs were found by  
188 Orthofinder v.2.4.0 [27]. Gene synteny was visualized by Cytoscape  
189 v.3.8.0 [28], according to a published script [29], with minute  
190 modification.

## 191 **Sequencing depth measurement**

192 To estimate the mean sequencing depth of each strain, SeqKit v.0.13.2  
193 [30] was used to calculate total base amount in reads and genome drafts  
194 of each strain. Seqtk v.1.3-r106 [31] was used to subsample short reads

195 randomly to approximately 100× of sequencing depth. Short reads were  
196 realigned to genome drafts by bwa-mem v.0.7.17 [24]. To assess the  
197 chromosome sequencing depth, single copy gene regions were selected to  
198 calculate their average depth with samtools v.1.11 [32] depth with option  
199 “-aa”. These single-copy genes were derived from BUSCO v.4.0.0  
200 *Pseudomonadales* ortholog database (10th edition) [33], which including  
201 782 single copy genes. Each strain contained 776 (99.3%) single-copy  
202 genes on average. Plasmid sequencing depth were represented by that of  
203 *repA* gene. To assess the copy numbers of *bla*<sub>KPC-2</sub> gene and two types of  
204 plasmids, the ratio of sequencing depth of each gene to those of the  
205 chromosome were calculated.

## 206 **Phylogeny**

207 *P. aeruginosa* genome drafts from NCBI Genbank database were  
208 download. The MLST type was detected by mlst v.2.19.0 [34]. Isolates  
209 with undefined sequencing type were submitted to PubMLST database  
210 [35] for new ST profiles. Orthofinder v.2.4.0 [27] with default options  
211 was used to cluster genes into orthologous groups. Sequences of single  
212 copy orthologues were aligned by mafft v.7.471 [36] with options  
213 (--maxiterate 1000 --localpair). Aligned genes of each strain were  
214 concatenated by a custom script to finish the multiple sequence alignment.  
215 The best nucleotide substitution models, GTR+I+G4, were selected by

216 ModelTest-NG v.0.1.6 [37] with option (-t ml). The maximum likelihood  
217 phylogenetic tree was generated by RAxML-NG v. 1.0.1 [38] with 100  
218 tree searches (50 random and 50 parsimony-based starting trees) and  
219 bootstrap replicates (autoMRE criterion). TreeCollapseCL4 [39] was used  
220 to collapse branches with <50% bootstrap support into polytomies. A  
221 circular tree layout with associated matrix was constructed by the R  
222 package *ggtree* v.2.2.4 [40].

### 223 **Acquired antimicrobial resistance genes and mutation-derived** 224 **antibiotic resistance mechanism**

225 Acquired antimicrobial resistance (AMR) genes were annotated by  
226 Abricate v.1.0.1 [41], using NCBI AMRFinderPlus database (April  
227 29,2020 updated) [42]. Only antibiotic genes with coverage greater than  
228 90% were included. Pseudomonas-derived cephalosporinase (PDC) and  
229 OXA-class  $\beta$ -lactamases were reexamined by BLASTX against amino  
230 acid sequences in NCBI AMRFinderPlus database.

231 To determine mutation-derived antibiotic resistance, a collection of 164  
232 antibiotic-resistance-related genes derived from a previous study was  
233 selected as candidates to investigate [43]. Most of previous studies treated  
234 model species *P. aeruginosa* PAO1 as the reference. However, natural  
235 variations were common among different sequence types. To minimize  
236 the false positive results, we chose strains from a previous study as the

237 references for each ST. A published dataset containing both genome  
238 sequences and antibiotic susceptibility results was treated as reference  
239 [44]. One strain of each ST was selected from meropenem-susceptible  
240 group in this dataset and our samples to compose an unduplicated set.  
241 According to the accessory genes content analyzed by roary v.3.13.0 [45],  
242 each representative strain of each ST in our sample paired with the most  
243 similar strain in the meropenem-susceptible group for variant calling.  
244 Variants were called by snippy v.4.6.0 [46], and only those in the 164  
245 AMR gene regions were selected. Variants were filtered according to base  
246 quality (Phred score) greater than 20 and minimum read depth greater  
247 than 20. For *oprD* gene, signal peptide was predicted by SignalP v.5.0  
248 portable version [47]. The *oprD* gene was inferred as nonfunctional if  
249 signal peptide is absent or an early stopped mutation occurred.

## 250 **Statistical analysis**

251 All statistical analysis were performed using R v.4.0.0-v.4.0.2 and  
252 Rstudio v.1.2.5001. Normality were detected by *shapiro.test* function in  
253 stats package v.4.0.0. Gene copy number comparisons among different  
254 MIC groups were done by *dunn.test* function in dunn.test package v.1.3.5,  
255 between different plasmid type groups were performed by *wilcox.test*  
256 function in stats package v.4.0.0. Correlation was calculated and tested by  
257 *cor*, *cor.test* functions in stats package v.4.0.0, respectively.



## 258 **Results**

### 259 **Geographic Distribution and Antimicrobial susceptibility**

260 A total of 374 CRPA clinical isolates were collected from seven  
261 hospitals in China, those were SRRSH (n=86), FAHZU (n=71), WTJH  
262 (n=50), PUMCH (n=50), NDTH (n=44), ZPPH (n=35) and QZPH (n=35).  
263 151 strains were *bla*<sub>KPC</sub>-positive based on PCR screens. All *bla*<sub>KPC</sub> genes  
264 were *bla*<sub>KPC-2</sub>. *bla*<sub>KPC-2</sub> gene were detected in CRPA isolates from all  
265 hospitals except PUMCH. The percentage of *bla*<sub>KPC-2</sub>-positive strains in  
266 CRPA varied among hospitals from 11.4% (NDTH) to 92.1% (ZPPH)  
267 (Figure 1). The antimicrobial susceptibility test on the 151 KPC-PA  
268 isolates showed high-level (>90%) resistance to fluoroquinolones and all  
269  $\beta$ -lactams except to CAZ-AVI (Table 1). 93.4% (141/151) of isolates met  
270 the criteria of DTR. Half of isolates (76/151) were susceptible to  
271 CAZ-AVI. MIC<sub>50/90</sub> of CAZ-AVI were 16/4 and 32/4 mg/L, respectively.  
272 The aminoglycosides resistance rates ranged from 4.0% to 8.6%. No  
273 strain was resistant to colistin. Three strains from NDTH were  
274 colistin-only-susceptible. Full AST results was shown in Supplementary  
275 Table 1.

### 276 **Molecular epidemiology**

277 Making use of Illumina sequencing data available for 151 KPC-PA, we

278 found that the multi-locus sequence type (MLST) detection indicated  
279 three main KPC-PA sequence types, ST463 (n=107), ST485 (n=14) and  
280 ST1212 (n=12), dominating in different geographic regions (Figure 1).  
281 ST463 was mainly found in cities in East China (Nanjing (5/5),  
282 Hangzhou (85/113) and Quzhou (17/19)), while ST485 (14/14) is the  
283 main KPC-PA of Wuhan in Central China (Figure 1).

#### 284 **Identification of KPC-encoding plasmids**

285 Making use of sequence alignments, we categorized putative plasmid  
286 contigs in each genome draft into three plasmid types. 118 and 19 strains  
287 contained Type 1 and 2 plasmids, respectively. One strain, ZPPH8,  
288 contained both. No Type 3 plasmid was detected in our samples (Table 2  
289 and Figure 2). The other 15 strains did not contain any of these three  
290 plasmid types.

#### 291 **Molecular characteristics of Type 1 plasmid**

292 A representative of the Type 1 plasmid was pSRRSH1002-KPC. This  
293 plasmid was 49,370 bp in length and had a GC content of 58%. Encoded  
294 on pSRRSH1002-KPC was a putative repA, a maintenance system and an  
295 incomplete type IV secretion system (T4SS) which indicated that this  
296 plasmid was not conjugative *per se*. To visualize the structure variation of  
297 this plasmid type, we performed a gene synteny analysis which clustered

298 genes of the same orthologs and highlighted the variant part comparing to  
299 the reference pSRRSH1002-KPC. From the gene synteny plot, we  
300 observed two major variations. One variation we observed was that some  
301 members of the Type 1 plasmid kept an intact T4SS. Another group was  
302 formed that characterized by gene deletions and inversions in the  
303 accessory region (Figure 3A).

304 Noticeably, pSRRSH1002-KPC harbored two *bla*<sub>KPC-2</sub> gene copies. The  
305 two *bla*<sub>KPC-2</sub> adjacent regions laid in an inversed repeated pattern,  
306 bounded by IS26. Each segment was identical to that on pKP048, the  
307 most common prototype of *bla*<sub>KPC-2</sub> adjacent region in China (Figure 3B)  
308 [48]. Most often, the flanking insertion sequence was that of  
309 IS26- $\Delta$ Tn6296. Tn6296 consisted of a core *bla*<sub>KPC-2</sub> platform,  
310  *$\Delta$ repB-orf1-klcA-orf2-korC- $\Delta$ kfrC- $\Delta$ ISKpn6-*bla*<sub>KPC-2</sub>-ISKpn27-Tn2*  
311 *tnpR- $\Delta$ Tn2 tnpA*, which inserted into Tn1722 [16]. The Tn2 *tnpA* gene  
312 was truncated at the 2,456 bp site. Furthermore, an IS26 intramolecular  
313 replicative transposition in *trans* truncated the Tn2 *tnpA* at the 81 bp site  
314 and inverted a 6,922-bp segment as verified by an 8-bp target site  
315 duplication (TSD, CGATATTT). Interestingly, different to other  
316 IS26-franked tandem repeat arrays, both repeated segments were  
317 separated by a  $\Delta$ IS26 and an intact IS26. The first 294 bp of  $\Delta$ IS26 was  
318 deleted.

319 We sequenced other two more plasmids, pSRRSH1101 and

320 pSRRSH1408-KPC. pSRRSH1101 was 29,640-bp in size. It had the  
321 identical backbone of pSRRSH1002-KPC. However, in pSRRSH1101,  
322 the insertion region that contained *bla*<sub>KPC-2</sub> gene was deleted (Figure 3C).  
323 pSRRSH1408-KPC was identical with pSRRSH1002-KPC with the  
324 exception of an IS26 -mediated deletion of one *bla*<sub>KPC-2</sub> gene (Figure 3C).

### 325 **Molecular characteristics of Type 2 plasmid**

326 pNDTH10366-KPC and pWTJH12-KPC belonged to a megaplasmid  
327 family[49, 50], referred as Type 2 plasmid here. As with other family  
328 members, these two plasmids carried a ParB-related ThiF-related cassette  
329 (PRTRC system), a chemotaxis operon, a partition system, a type II  
330 secretion system, a radical SAM operon, a tellurite resistance operon and  
331 a T4SS on its backbone. The gene synteny plot illustrated the backbone  
332 was stable and variable region was composed of different mobile genetic  
333 elements containing multiple AMR genes including  $\beta$  -lactamases  
334 *bla*<sub>KPC-2</sub>, *bla*<sub>AFM</sub> and *bla*<sub>OXA-246</sub> (Figure 4).

### 335 **IS6100-related composite transposon mediated *bla*<sub>KPC-2</sub> gene** 336 **transmission**

337 pWTJH12-KPC contained one *bla*<sub>KPC-2</sub> gene. The genetic context  
338 adjacent to *bla*<sub>KPC-2</sub> was identical to that on the Type 1 plasmid with  
339 p14057-KPC as a representative; in both plasmids the gene is embedded

340 in IS6100- $\Delta$ Tn6296-Tn1403 [16]. This suggested that this mobile genetic  
341 element (MGE) carrying *bla*<sub>KPC-2</sub> might be able to transfer between two  
342 plasmid types, especially in case of ZPPH8 which contained both  
343 plasmids. The Type 2 plasmid containing the genetic context in which the  
344 *bla*<sub>KPC-2</sub> was embedded, had been recently reported in Tianjin, China [18].  
345 Interestingly, a sequence alignment showed that plasmid pNK546-KPC  
346 underwent large segment inversion next to the *bla*<sub>KPC-2</sub> region (Figure 5).  
347 The similarities within the genetic contexts indicated frequent exchange  
348 events and transmission of *bla*<sub>KPC-2</sub>-containing genome segments among  
349 the strains we investigated, despite of their different sequence types.

### 350 **Comparison of two KPC-encoding plasmid types**

351 Since most of the *bla*<sub>KPC-2</sub> gene were located on plasmids, we  
352 hypothesized that plasmid types and plasmid copy numbers might  
353 contribute to the *bla*<sub>KPC-2</sub> gene multiple copy in each strain. To verify our  
354 hypothesis, Illumina sequencing depths of all sequenced isolates were  
355 measured. Compared to Type 2 plasmid, Type 1 plasmid exhibited 1.2  
356 more copies per cell (2.36 vs. 1.20,  $p=1.5\times 10^{-10}$ , see Table 3). Strains  
357 containing Type 1 plasmid harbored 1.4 more *bla*<sub>KPC-2</sub> gene on average  
358 than those containing Type 2 plasmid (2.56 vs. 1.15,  $p=1.07\times 10^{-7}$ , see  
359 Table 3).

### 360 ***bla*<sub>KPC-2</sub> gene on chromosome**

361 Although most *bla*<sub>KPC-2</sub> genes were located on plasmids, we identified  
362 two KPC-PA strains harbored *bla*<sub>KPC-2</sub> gene on the chromosome.

363 In the *P. aeruginosa* strain NDTH10366, a *bla*<sub>KPC-2</sub> gene array was  
364 found on the chromosome which consisted of three IS26-mediated  
365 tandem-repeat *bla*<sub>KPC-2</sub> adjacent segments. Strains from SRRSH that  
366 belonged to ST244, also contained a chromosome-embedded *bla*<sub>KPC-2</sub>  
367 gene. The genome of a representative strain SRRSH15 consisted of a  
368 single circular 6.7-Mb-long contig. An IS6100-flanked composite  
369 transposon with a size of 17,797 bp inserted into the chromosome at the  
370 site of a putative hydrolase gene, leaving 8-bp TSD (GGCAAGCC)  
371 (Figure 5). These findings indicated intracellular transposition occurred in  
372 *P. aeruginosa* and participated in shaping *P. aeruginosa* genomes.

### 373 **The effect of the *bla*<sub>KPC-2</sub> copy number and other AMR genes on** 374 **CAZ-AVI susceptibility**

375 In our samples, all strains exhibited high-level resistance to  
376 carbapenems while the susceptibility to CAZ-AVI varied in a large range  
377 (2-512mg/L). We further investigated the correlation between CAZ-AVI  
378 MIC values and multiple *bla*<sub>KPC-2</sub> gene copies mediated by both plasmid  
379 multiple copies and IS26 or IS6100 duplicative transposition. We  
380 excluded two strains containing MBLs (NDTH7329 and NDTH10366)

381 when analyzing the effect of the *bla*<sub>KPC-2</sub> copy number on CAZ-AVI  
382 susceptibility. The *bla*<sub>KPC-2</sub> gene copy number correlated with the  
383 CAZ-AVI MIC values (Pearson coefficient 0.326, 95% CI 0.174-0.463,  
384  $p < 0.0001$ ). Significant differences of the *bla*<sub>KPC-2</sub> gene copy number were  
385 observed among CAZ-AVI MIC groups (2-32mg/L, Figure 6A). However,  
386 when values of the high-level resistance ( $\geq 64$ mg/L) were observed, the  
387 relationship was less obvious, possibly due to the comparably fewer  
388 number of strains exhibiting high-level resistance to CAZ-AVI (n=6).

389 Besides the acquisition of *bla*<sub>KPC-2</sub> gene, other chromosomal mutations  
390 also contributed to carbapenem and CAZ-AVI resistance. The *oprD* gene  
391 encoded the outer membrane porin D which allowed the diffusion of  
392 carbapenems into *P. aeruginosa*. In this study, all *oprD* genes could be  
393 classified into 18 types based on amino acid sequences similarity.  
394 124/151(82.1%) strains were presumed to contain a nonfunctional *oprD*  
395 gene, mediating reduced sensitivity to carbapenems. The majority of  
396 nonfunctional *oprD* genes were found in ST463, ST244 and ST1212  
397 strains. All *oprD* genes in the clinical isolates from WTJH and NDTH  
398 exhibit no mutations, indicating the expression of functional proteins  
399 (Figure 2 and Supplementary Table 2).

400 Carbapenem and CAZ-AVI resistance could also be mediated by the  
401 F533L mutation in the *ftsI* gene which encoded penicillin-binding protein  
402 3 (PBP3) (Figure 2 and Supplementary Table 2). In 107 isolates that

403 belonged to ST463 strains, we found almost all of them (n=105)  
404 contained a T1597C nucleotide mutation in the *ftsI* gene, which lead to  
405 the F533L substitution in PBP3. All twelve ST1212 isolates displayed a  
406 so far uncharacterized mutation in the *ftsI* gene (A271G) and  
407 correspondingly T91A amino acid substitution in PBP3 which has not yet  
408 been studied regarding potential carbapenem or CAZ-AVI resistance  
409 mechanisms.

410 Since these variables such as mutations in PBP3 or porin D might  
411 contribute to the observed resistance values besides the acquisition of  
412 *bla*<sub>KPC-2</sub> gene. In order to analyze the contribution of each variable to  
413 CAZ-AVI resistance, we analyzed the impact of *bla*<sub>KPC-2</sub> gene copy  
414 number in a more homogenous genetic background. We selected a subset  
415 which consisted of 100 ST463 strains with the F533L substitution in  
416 PBP3 and nonfunctional porin D, while harboring the Type 1 plasmid. In  
417 this subset, significant difference was only detected between 8 and  
418 16mg/L groups (p=0.002, Figure 6B). Again, it might be explained by  
419 fewer samples in other groups.

420 We also investigated the effect of multiple *bla*<sub>KPC-2</sub> genes copies on a  
421 single plasmid to CAZ-AVI susceptibility. We used the ratio of *bla*<sub>KPC-2</sub>  
422 gene sequence depth to the *repA* gene sequence depth as the relative  
423 *bla*<sub>KPC-2</sub> gene copies per plasmid. We defined the ratio less than 1.5 as  
424 single *bla*<sub>KPC-2</sub> gene per plasmid (Single) and that greater than 1.5 as



425 multiple *bla*<sub>KPC-2</sub> gene copies per plasmid (Multi) (Figure 6C and 6D). In  
426 134 strains containing Type 1 or Type 2 plasmid, the CAZ-AVI MIC  
427 values were significantly different between the Single and the Multi  
428 groups ( $p=1.6e-7$ , see Table 4). This result was still hold in the ST463  
429 subset mentioned above ( $p=5.8e-5$ , see Table 5). In both subsets, the  
430 plasmid copy numbers were not significantly different. Of note, the Multi  
431 group showed a right-shifting tendency of the CAZ-AVI MIC distribution  
432 compared to the Single group (Figure 6E and 6F). These results indicated  
433 that multiple *bla*<sub>KPC-2</sub> gene copies caused by insertion-sequence-mediated  
434 duplication contributed to CAZ-AVI MIC elevation.

435 Other carbapenem or CAZ-AVI resistance related genes including  
436 *Pseudomonas*-derived cephalosporinase (PDC) and efflux pumps  
437 especially the MexAB-OprM. PDC was a constitutional  $\beta$ -lactamase in *P.*  
438 *aeruginosa* that was able to hydrolyze cephalosporins. PDCs were found  
439 to correlate with the sequence types. The *bla*<sub>PDC-8</sub>, *bla*<sub>PDC-6</sub>, *bla*<sub>PDC-3</sub> genes  
440 were identified in three main STs, ST463, ST485 and ST1616,  
441 respectively. No amino acid substitutions which might contribute to  
442 CAZ-AVI resistance were detected in our samples. No so far  
443 known-of-function mutations in efflux pump genes was detected. In  
444 addition to *bla*<sub>KPC-2</sub>, acquired  $\beta$ -lactamases observed in individual strains  
445 were *bla*<sub>CARB-2</sub>, *bla*<sub>OXA-10</sub> family  $\beta$ -lactamase *bla*<sub>OXA-246</sub> and a novel MBL  
446 *bla*<sub>AFM</sub>.

447 Comprehensive AMR-related mutations or acquired AMR genes were  
448 listed in Supplementary Table 2.

## 449 Discussion

450 In this study, we focused on a specific subpopulation of CRPA, that  
451 was KPC-PA. At the point of time when the bacteria were isolated, the  
452 KPC-PA strains showed moderate susceptibility to CAZ-AVI. The MICs  
453 of approximately 70% of the strains were at the margin of breakpoint  
454 (8/4-16/4 mg/L). In our samples, we identified two main KPC-related  
455 plasmids. Type 1 plasmid was predominant; however, most were found in  
456 ST463 strains and their distribution was limited in Eastern China. In  
457 contrast to this, Type 2 plasmid was spread more widely and existed in  
458 many diverse sequence types. Deploying Nanopore long-read sequencing,  
459 we deciphered *bla*<sub>KPC-2</sub> genetic characteristics in this work. We found that  
460 the *bla*<sub>KPC-2</sub> copy number variation was caused by mobile genetic  
461 elements, in particular by IS26, mediating transposition. Our results also  
462 revealed that multiple copies of the *bla*<sub>KPC-2</sub> gene correlated with elevated  
463 CAZ-AVI MIC values.

464 Previous epidemiological surveillance studies had focused on CRPA.  
465 One of the largest studies performed in China reported a resistance rate of  
466 CRPA to CAZ-AVI was 34.3% in 2017 [51] and 35.7% in 2018 [52].  
467 The strains investigated in our study were collected around the same time

468 (2017-2018). The isolated KPC-PA strains exhibited a higher CAZ-AVI  
469 resistance rate than all the CRPA. In the previous studies, no screening  
470 was performed regarding the *bla*<sub>KPC-2</sub> gene, which in retrospect showed  
471 the unawareness of which important role this AMR gene played in *P.*  
472 *aeruginosa*. As for the origin of *bla*<sub>KPC-2</sub> gene in *P. aeruginosa*, it was fair  
473 to infer that the gene was introduced into *P. aeruginosa* by interspecies  
474 transmission since the genomic environment of the *bla*<sub>KPC-2</sub> gene was near  
475 identical and closely related to the gene that has first been described in *K.*  
476 *pneumoniae*. Data from the above-mentioned study [53] indicated that  
477 ~65 % carbapenem-resistant *K. pneumoniae* in China carried the *bla*<sub>KPC-2</sub>  
478 gene, which made it the most prevalent carbapenemase in this species.  
479 Interestingly, 100% of *bla*<sub>KPC-2</sub>-carrying *Enterobacteriaceae* were  
480 susceptible to CAZ-AVI [53], which stood in contrast to 50%  
481 susceptibility in KPC-PA which we observed in this study. It suggested  
482 that the acquisition of *bla*<sub>KPC-2</sub> impacted the CAZ-AVI susceptibility in *P.*  
483 *aeruginosa* in more substantial extent than in *Enterobacteriaceae*. In  
484 general, it becomes clear that screening for *bla*<sub>KPC</sub> in CRPA was  
485 important.

486 Our study also investigated the impact of *bla*<sub>KPC-2</sub> copy number  
487 variation. It was reasonable to assume that there was a correlation  
488 between the *bla*<sub>KPC-2</sub> copy number and CAZ-AVI resistance. Previous  
489 studies had demonstrated  $\beta$ -lactamase gene amplification correlated with

490 the susceptibility to  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combination agents  
491 [54-56]. Our results supported these conclusions. An important  
492 mechanism of AMR gene amplification was insertion-sequence  
493 (IS)-mediated duplication. In our study, *bla*<sub>KPC-2</sub> was located on two  
494 mobile genetic elements, IS26- $\Delta$ Tn6296 and IS6100- $\Delta$ Tn6296-Tn1403.  
495 IS26-mediated module appeared to promote genetic element transposition,  
496 for example tandem or inversed repeats and from plasmid to chromosome.  
497 IS26 was strongly linked to horizontal AMR gene transfer [57]. Two  
498 mechanisms of IS26 movements had been demonstrated previously, that  
499 was the replicative transition and the conserved targeted transition [57,  
500 58]. The characteristic 8-bp TSD can help to trace IS26 transposition.  
501 From our data, we could conclude that the *bla*<sub>KPC-2</sub> copy number variation  
502 among strains harboring Type 1 plasmid was mediated by the conserved  
503 targeted transition. In later statistical study, we found that IS-mediated  
504 gene amplification contributed to CAZ-AVI MIC elevation. It caveated  
505 that the antimicrobial susceptibility test was necessary to surveil during  
506 the treatment course, since the MIC might fluctuate due to IS-mediated  
507 copy number variation.

508 Five *P. aeruginosa* plasmids carrying *bla*<sub>KPC-2</sub> reported in China had  
509 been identified on the NCBI database (Table 2). Type 1 plasmid defined  
510 in this study was reported first by Shi et al [16] and later by Hu et al [17].  
511 In this work, we provide high-precision sequencing data of three more

512 Type 1 plasmids with different *bla*<sub>KPC-2</sub> gene copy numbers. Type 2  
513 plasmids belonged to a megaplasmid family which had been reviewed  
514 recently [49, 50]. Members of this family displayed a size of 300-500 Kb  
515 and several AMR genes. However, those carrying *bla*<sub>KPC-2</sub> genes were  
516 only reported in China [18, 59]. The current study showed that this  
517 megaplasmid spread widely around the country as we identified the  
518 plasmid in Eastern and Central China. The third plasmid type, reported in  
519 other publications, was not detected in this study, indicating that this  
520 plasmid type might be not prevalent in regions we sampled. However,  
521 two previously reported cases of the third plasmid type were found in  
522 China in two different regions of the country [59], which suggested that  
523 the third plasmid type was not rare. Fifteen strains in the current study  
524 had undefined *bla*<sub>KPC-2</sub> gene location (chromosome or plasmid). The  
525 previously published data and our current work illustrates that a more  
526 comprehensive surveillance study was required in the future to elucidate  
527 the epidemiology of KPC-PA in China.

528 The two main plasmid types exhibited different geographical  
529 distributions. This might be explained by the time that has passed since  
530 the plasmids were incorporated by *P. aeruginosa* strains. Type 1 plasmids  
531 had been found in *P. aeruginosa* for approximately one decade [13],  
532 while the earliest strain harboring Type 2 plasmid could be traced back to  
533 the 1980s [50]. In addition, the host range of Type 1 plasmid was

534 comparatively small, while the Type 2 plasmid family had been found in  
535 other Pseudomonal and non-Pseudomonal genera [50]. This might be  
536 explained by the fact that the conjugal ability of Type 2 plasmid has been  
537 demonstrated experimentally [18], in contrast to Type 1 plasmids.  
538 However, the high pressure of carbapenem usage in clinics might  
539 accelerate the occurrence of *P. aeruginosa* harboring *bla*<sub>KPC-2</sub> genes and  
540 retain such strains in the nosocomial environment, leading to dominant  
541 clones such as ST463.

542 The limited sampling locations of the strains, which originated mainly  
543 from Eastern China, presents a limitation of our study, as the real  
544 prevalence of KPC-PA over the whole country remained uncertain. As  
545 discussed above, our investigation could be seen as a pilot study and thus  
546 we highly recommended to screen for *bla*<sub>KPC</sub> genes in nationwide  
547 antimicrobial surveillance studies, or those being undertaking by other  
548 nations. Another potential limitation was that we determined plasmids in  
549 each strain by mapping sequencing reads to representative plasmids. We  
550 understood that this approach did not guarantee to identify correctly on  
551 which replicon the *bla*<sub>KPC-2</sub> gene was located. However, we believed that  
552 it was reasonable to assume that strains of the same ST were highly  
553 similar in the genetic background to the representative strains that we  
554 sequenced completely. Indeed, this approach had also been implemented  
555 in a recent large-scale carbapenemase-harboring plasmid analysis [60].

556

## 557 Conclusions

558 In summary, our study clearly shows that KPC-PA strains represent a  
559 threat to the healthcare system in China. Therefore, we propose to screen  
560 *bla*<sub>KPC</sub> genes in *P. aeruginosa* isolates in nationwide surveillance projects.  
561 As this issue is not only affecting China but is of global concern, further  
562 studies investigating the same topic on a global scale would help to  
563 understand the epidemiology of KPC-PA strains in the entire human  
564 population. We believe such studies might be able to guide therapeutic  
565 deploying CAZ-AVI for the treatment of KPC-PA infections.

566

## 567 **Declarations**

### 568 **Ethics approval and consent to participate**

569 Approval was obtained from the Ethics Committee of Sir Run Run  
570 Shaw Hospital (approval/reference number: 20201118-49). This study  
571 was not considered as a human research. Therefore, no informed consent  
572 to participate was required. This study conformed to the principles of the  
573 Helsinki Declaration.

### 574 **Consent for publication**

575 Not applicable

### 576 **Availability of data and material**

577 All the sequence data were deposited at DDBJ/ENA/GenBank under  
578 the BioProject accession number PRJNA672835.

### 579 **Competing interests**

580 The authors declare that they have no competing interests.

### 581 **Funding**

582 This study is supported by the National Natural Science Foundation of  
583 China (grant no. 81830069).

### 584 **Authors' contributions**

585 Y.Y conceived, designed, and coordinated this study. Y.Z. and J.C.  
586 performed the microbiological cultures of the isolates and antimicrobial  
587 susceptibility tests. Y.Z and X.H. analyzed the genome sequencing data.  
588 H.S., Z.C., Q.Y., J.Z., X.L, Q.Y. and F.Z. collected the isolates from  
589 respective hospitals. J.J., H.C., Y.L. and L.Z. provided help to extract  
590 genome DNA and perform genome sequencing. Y.Z. wrote the initial  
591 version of the manuscript. X.H., S.L. and Y.Y. revised the manuscript. All  
592 authors read and approved the final manuscript.

### 593 **Acknowledgments**

594 Not applicable

595

596

597

## **References:**

- 598 1. Tacconelli E *et al.* Discovery, research, and development of new antibiotics: the WHO priority list  
599 of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 2018, 18(3):318-327.
- 600 2. Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA. Resistance to Novel  $\beta$ -Lactam- $\beta$



- 601 -Lactamase Inhibitor Combinations. *Infect Dis Clin N Am* 2020, 34(4):773-819.
- 602 3. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam:
- 603 Second-generation  $\beta$ -Lactam/  $\beta$ -Lactamase Inhibitor Combinations. *Clin Infect Dis* 2016,
- 604 63(2):234-241.
- 605 4. Karlowsky JA *et al.* In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of
- 606 *Enterobacteriaceae* and *Pseudomonas aeruginosa* Collected in Latin American Countries: Results
- 607 from the INFORM Global Surveillance Program, 2012 to 2015. *Antimicrob Agents Chemother* 2019,
- 608 63(4):e1814-e1818.
- 609 5. Karlowsky JA *et al.* In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of
- 610 *Enterobacteriaceae* and *Pseudomonas aeruginosa* Collected in Asia-Pacific Countries: Results from
- 611 the INFORM Global Surveillance Program, 2012 to 2015. *Antimicrob Agents Chemother* 2018,
- 612 62(7):e2517-e2569.
- 613 6. Kazmierczak KM, de Jonge B, Stone GG, Sahn DF. In Vitro Activity of Ceftazidime/Avibactam
- 614 against Isolates of *Pseudomonas aeruginosa* Collected in European Countries: INFORM Global
- 615 Surveillance 2012-15. *J Antimicrob Chemother* 2018, 73(10):2777-2781.
- 616 7. Villegas MV *et al.* First identification of *Pseudomonas aeruginosa* isolates producing a KPC-type
- 617 carbapenem-hydrolyzing beta-lactamase. *Antimicrob Agents Chemother* 2007, 51(4):1553-1555.
- 618 8. Naas T *et al.* Genetic structures at the origin of acquisition of the beta-lactamase  $bla_{KPC}$  gene.
- 619 *Antimicrob Agents Chemother* 2008, 52(4):1257-1263.
- 620 9. Poirel L, Nordmann P, Lagrutta E, Cleary T, Munoz-Price LS. Emergence of KPC-producing
- 621 *Pseudomonas aeruginosa* in the United States. *Antimicrob Agents Chemother* 2010, 54(7):3072.
- 622 10. Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-Driven  $\beta$ -Lactam Resistance
- 623 Mechanisms among Contemporary Ceftazidime-Nonsusceptible *Pseudomonas aeruginosa* Isolates
- 624 from U.S. Hospitals. *Antimicrob Agents Chemother* 2014, 58(11):6844-6850.
- 625 11. Hagemann JB, Pfennigwerth N, Gatermann SG, von Baum H, Essig A. KPC-2
- 626 carbapenemase-producing *Pseudomonas aeruginosa* reaching Germany. *J Antimicrob Chemother* 2018,
- 627 73(7):1812-1814.
- 628 12. Galetti R, Andrade LN, Varani AM, Darini ALC. A Phage-Like Plasmid Carrying  $bla_{KPC-2}$  Gene
- 629 in Carbapenem-Resistant *Pseudomonas aeruginosa*. *Front Microbiol* 2019, 10:572.
- 630 13. Ge C *et al.* Identification of KPC-2-producing *Pseudomonas aeruginosa* isolates in China. *J*
- 631 *Antimicrob Chemother* 2011, 66(5):1184-1186.
- 632 14. Hu Y, Gu D, Cai J, Zhou H, Zhang R. Emergence of KPC-2-Producing *Pseudomonas aeruginosa*
- 633 Sequence Type 463 Isolates in Hangzhou, China. *Antimicrob Agents Chemother* 2015,
- 634 59(5):2914-2917.
- 635 15. Naas T, Bonnin RA, Cuzon G, Villegas MV, Nordmann P. Complete sequence of two
- 636 KPC-harboring plasmids from *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 2013,
- 637 68(8):1757-1762.
- 638 16. Shi L *et al.* Coexistence of two novel resistance plasmids,  $bla_{KPC-2}$ -carrying p14057A and
- 639 tetA(A)-carrying p14057B, in *Pseudomonas aeruginosa*. *Virulence* 2018, 9(1):306-311.
- 640 17. Hu Y, Wang Q, Sun Q, Chen G, Zhang R. A novel plasmid carrying carbapenem-resistant gene
- 641  $bla_{KPC-2}$  in *Pseudomonas aeruginosa*. *Infect Drug Resist* 2019, Volume 12:1285-1288.
- 642 18. Li Z *et al.* Molecular genetic analysis of an XDR *Pseudomonas aeruginosa* ST664 clone carrying

- 643 multiple conjugal plasmids. *J Antimicrob Chemother* 2020, 75(6):1443-1452.
- 644 19. Abril D *et al.* Genome plasticity favours double chromosomal Tn4401b-*bla*<sub>KPC-2</sub> transposon  
645 insertion in the *Pseudomonas aeruginosa* ST235 clone. *Bmc Microbiol* 2019, 19(1):45.
- 646 20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial  
647 Susceptibility Testing CLSI supplement M100. In., 30th edn. Wayne, PA, USA: Clinical and  
648 Laboratory Standards Institute; 2020.
- 649 21. Tamma PD *et al.* Infectious Diseases Society of America Guidance on the Treatment of  
650 Antimicrobial Resistant Gram-Negative Infections. *Clin Infect Dis* 2020, ciaa1478.
- 651 22. Seemann T. <https://github.com/tseemann/shovill>
- 652 23. Bankevich A *et al.* SPAdes: a new genome assembly algorithm and its applications to single-cell  
653 sequencing. *J Comput Biol* 2012, 19(5):455-477.
- 654 24. Heng L. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv*  
655 2013:1303-3997.
- 656 25. Marçais G *et al.* MUMmer4: A fast and versatile genome alignment system. *Plos Comput Biol*  
657 2018, 14(1):e1005944.
- 658 26. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014,  
659 30(14):2068-2069.
- 660 27. Emms DM, Kelly S. OrthoFinder: phylogenetic orthology inference for comparative genomics.  
661 *Genome Biol* 2019, 20(1):238.
- 662 28. Shannon P *et al.* Cytoscape: a software environment for integrated models of biomolecular  
663 interaction networks. *Genome Res* 2003, 13(11):2498-2504.
- 664 29. Weisberg AJ *et al.* Unexpected conservation and global transmission of agrobacterial virulence  
665 plasmids. *Science* 2020, 368(6495).
- 666 30. Shen W, Le S, Li Y, Hu F. SeqKit: A Cross-Platform and Ultrafast Toolkit for FASTA/Q File  
667 Manipulation. *Plos One* 2016, 11(10):e163962.
- 668 31. Heng L. <https://github.com/lh3/seqtk>
- 669 32. Li H *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009,  
670 25(16):2078-2079.
- 671 33. Seppy M, Manni M, Zdobnov EM. BUSCO: Assessing Genome Assembly and Annotation  
672 Completeness. *Methods Mol Biol* 2019, 1962:227-245.
- 673 34. Seemann T. <https://github.com/tseemann/mlst>
- 674 35. Jolley KA, Bray JE, Maiden M. Open-access bacterial population genomics: BIGSdb software,  
675 the PubMLST.org website and their applications. *Wellcome Open Res* 2018, 3:124.
- 676 36. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements  
677 in performance and usability. *Mol Biol Evol* 2013, 30(4):772-780.
- 678 37. Darriba D *et al.* ModelTest-NG: A New and Scalable Tool for the Selection of DNA and Protein  
679 Evolutionary Models. *Mol Biol Evol* 2020, 37(1):291-294.
- 680 38. Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAXML-NG: a fast, scalable and  
681 user-friendly tool for maximum likelihood phylogenetic inference. *Bioinformatics* 2019,  
682 35(21):4453-4455.
- 683 39. Hodcroft E. <http://emmahodcroft.com/TreeCollapseCL.html>
- 684 40. Yu G, Smith DK, Zhu H, Guan Y, Lam TT. GGTREE: an R package for visualization and  
685 annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol Evol*  
686 2017, 8(1):28-36.

- 687 41. Seemann T. <https://github.com/tseemann/abricate>
- 688 42. Feldgarden M *et al.* Validating the AMRFinder Tool and Resistance Gene Database by Using  
689 Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. *Antimicrob*  
690 *Agents Chemother* 2019, 63(11):e419-e483.
- 691 43. Del BE *et al.* Genomics and Susceptibility Profiles of Extensively Drug-Resistant *Pseudomonas*  
692 *aeruginosa* Isolates from Spain. *Antimicrob Agents Chemother* 2017, 61(11).
- 693 44. Kos VN *et al.* The Resistome of *Pseudomonas aeruginosa* in Relationship to Phenotypic  
694 Susceptibility. *Antimicrob Agents Ch* 2014, 59(1):427-436.
- 695 45. Page AJ *et al.* Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 2015,  
696 31(22):3691-3693.
- 697 46. Seemann T. <https://github.com/tseemann/snippy>
- 698 47. Almagro AJ *et al.* SignalP 5.0 improves signal peptide predictions using deep neural networks.  
699 *Nat Biotechnol* 2019, 37(4):420-423.
- 700 48. Shen P *et al.* Novel Genetic Environment of the Carbapenem-Hydrolyzing-Lactamase KPC-2  
701 among Enterobacteriaceae in China. *Antimicrob Agents Ch* 2009, 53(10):4333-4338.
- 702 49. Jiang X *et al.* Plasmids of novel incompatibility group Inc<sub>pRBL16</sub> from *Pseudomonas* species. *J*  
703 *Antimicrob Chemoth* 2020, 75(8):2093-2100.
- 704 50. Cazares A *et al.* A megaplasmid family driving dissemination of multidrug resistance in  
705 *Pseudomonas*. *Nat Commun* 2020, 11(1):1370.
- 706 51. Yin D *et al.* Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of  
707 the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical  
708 Isolates of Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2019,  
709 63(4):e2418-e2431.
- 710 52. Yang Y *et al.* In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam and Other  
711 Comparators against Clinical Isolates of Enterobacterales, *Pseudomonas aeruginosa* and  
712 *Acinetobacter baumannii*: Results from China Antimicrobial Surveillance Network (CHINET) in 2018.  
713 *Antimicrob Agents Chemother* 2020:e1720-e1726.
- 714 53. Han R *et al.* Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among  
715 Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. *Front*  
716 *Cell Infect Mi* 2020, 10:314.
- 717 54. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-Vaborbactam  
718 Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing  
719 *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2017, 61(12):e409-e420.
- 720 55. Schechter LM *et al.* Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam  
721 Resistance in *Escherichia coli*. *Mbio* 2018, 9(2):e518-e583.
- 722 56. Coppi M *et al.* Ceftazidime-Avibactam Resistance Associated with Increased *bla*<sub>KPC-3</sub> Gene Copy  
723 Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 *Klebsiella pneumoniae*.  
724 *Antimicrob Agents Chemother* 2020, 64(4):e1816-e1819.
- 725 57. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile Genetic Elements Associated with  
726 Antimicrobial Resistance. *Clin Microbiol Rev* 2018, 31(4):e17-e88.
- 727 58. He S *et al.* Insertion Sequence IS26 Reorganizes Plasmids in Clinically Isolated  
728 Multidrug-Resistant Bacteria by Replicative Transposition. *Mbio* 2015, 6(3):e762.
- 729 59. Dai X *et al.* The IncP-6 Plasmid p10265-KPC from *Pseudomonas aeruginosa* Carries a Novel  $\Delta$

730 ISEc33-Associated *bla*<sub>KPC-2</sub> Gene Cluster. *Front Microbiol* 2016, 7:310.  
731 60. David S *et al.* Integrated chromosomal and plasmid sequence analyses reveal diverse modes of  
732 carbapenemase gene spread among *Klebsiella pneumoniae*. *Proc Natl Acad Sci U S A* 2020,  
733 117(40):25043-25054.  
734  
735

736

737 **Table 1** *In vitro* Antimicrobial Susceptibility Tests of KPC-producing *P. aeruginosa* from 6 Hospitals  
738 in China

Antibiotics	MIC (mg/L)			percentage resistance
	MIC <sub>50</sub>	MIC <sub>90</sub>	MIC range	
piperacillin/tazobactam	>256	>256	4->256	99.34
ceftazidime	128	256	4->256	100.00
cefepime	>256	>256	2->256	99.34
imipenem	>128	>128	8->128	100.00
meropenem	>128	>128	1->128	100.00
aztreonam	>128	>128	4->128	100.00
ceftazidime/avibactam	16	32	1->64	50.33
amikacin	4	16	1->64	3.97
gentamycin	4	8	0.25->64	8.61
tobramycin	1	2	0.25->64	3.97
ciprofloxacin	>16	>16	0.12->16	94.04
levofloxacin	>32	>32	0.25->32	93.38
colistin	0.5	0.5	<0.03-2	0.00

739

740 **Table 2** Three main types of KPC-encoding plasmids in *P. aeruginosa* from China

Plasmid Type defined in this study	No. in this study	Inc type	Plasmid names (accession numbers in NCBI database)
Type 1	118	Undefined	p14057-KPC(KY296095) p1011-KPC2(MH734334)
Type 2	19	IncP-3-like	pNK546-KPC(MN433457)
Type 3	0	IncP-6	p10265-KPC(KU578314) p1(CP040685)

No. numbers; Inc: incompatibility

741

742 **Table 3** Comparison between strains containing Type 1 and Type 2 plasmids

	Type 1 (n=117)	Type 2 (n=17)	p value
plasmid copy	2.36 (1.93-2.98)	1.2 (1.15-1.29)	1.45E-10
<i>bla</i> <sub>KPC-2</sub> gene copy	2.56 (2.03-3.49)	1.15 (1.06-1.30)	1.07E-07

The medians are shown. In brackets indicate interquartile ranges. p values are calculated by Wilcoxon test.

743

744 **Table 4** Comparison between single and multiple *bla*<sub>KPC-2</sub> gene copies per plasmid groups in 134  
745 strains containing Type 1 or 2 plasmids

	Single (n=102)	Multi (n=32)	p value
log <sub>2</sub> (CAZ-AVI MIC)	3 (3-4)	4 (4-5)	1.63E-07

plasmid copy	2.32 (1.72-2.90)	2.07 (1.75-2.45)	3.60E-01
--------------	------------------	------------------	----------

The medians are shown. In brackets indicate interquartile ranges. p values are calculated by Wilcoxon test.

746

747

748 **Table 5 Comparison between single and multiple *bla*<sub>KPC-2</sub> gene copies per plasmid groups in 100**  
749 **ST463 strains**

	Single (n=70)	Multi (n=30)	p value
log <sub>2</sub> (CAZ-AVI MIC)	4 (3-4)	4 (3-4)	5.80E-05
plasmid copy	2.39 (1.94-3.03)	2.09 (1.78-2.49)	0.1003

The medians are shown. In brackets indicate interquartile ranges. p values are calculated by Wilcoxon test.

750

751

752 **Figure 1. Geographical distribution of strains in this study.** The percentages in the figure

753 represent the percentage of KPC-PA in CRPA from each hospital. Each pie size indicates

754 sample size of each hospital. PUMCH: Peking Union Medical College Hospital; WTJH:

755 Wuhan Tongji Hospital; NDTH: Nanjing Drum Tower Hospital; FAHZU: the First Affiliated

756 Hospital of Zhejiang University; SRRSH: Sir Run Run Shaw Hospital; ZPPH: Provincial

757 People's Hospital of Zhejiang; QZPH: Quzhou People's Hospital.

758

759 **Figure 2. Core genome phylogenetic tree and carbapenem/CAZ-AVI resistance-related**

760 **genes.** Innermost layer is a maximum-likelihood phylogenetic tree of KPC-PA. colors of tip

761 labels indicate sequence type (ST), and shapes indicate plasmid types in each strain. The

762 unknown plasmid type suggests strain does not contain Type 1 or 2 plasmid and *bla*<sub>KPC-2</sub>

763 gene is located on another replicon. The second ring indicates cities where the strain is

764 isolated. The next three rings indicate MICs of imipenem, meropenem and CAZ-AVI,

765 respectively. The sixth ring represents loss-of-function mutation in *oprD* gene. The

766 seventh ring represents F533L mutation in PBP3. The eighth ring indicates estimated  
767 *bla*<sub>KPC-2</sub> gene copy number. The stars in the outmost ring indicate novel MBL *bla*<sub>AFM</sub>.

768

769 **Figure 3. Type 1 plasmid schematic plot and sequence alignment. A. pSRRSH1002-KPC**

770 **structure and Type 1 plasmid gene synteny.** The innermost layer indicates gene synteny

771 of Type 1 plasmids. The arrows in second ring from the innermost indicate genes on

772 SRRSH1002, which are in accordant with points of the gene synteny layers. Orange

773 indicate transposase, red indicates *bla*<sub>KPC-2</sub> gene, light-orange indicates genes in the

774 insertion region, green indicates conjugal elements, light-purple indicates *repA* gene. The

775 third ring shows backbone(grey) and insertion region(black) of the plasmid. The forth ring

776 represent GC skew, where yellow means skew to A and T and blue means skew to G and

777 C. The outmost ring represents GC content, where light-green represent GC% greater

778 than the median and dark-pink represents GC% less than the median (sliding window of

779 500bp). **B. Alignment of insertion regions on SRRSH1002-KPC and pKP048.** Arrows

780 denoted to genes or truncated genes. Alignment identity ranges from 97% to 100%.

781 GenBank accession: pRA3 (DQ401103), pKP048 (FJ628167), Tn4401 from pCOL-1

782 (KC609323), Tn2 (AY123253). **C. IS26-mediated *bla*<sub>KPC-2</sub> gene copy number variation in**

783 **Type 1 plasmid.** Firstly, start from Precursor plasmid contained an IS26-flanked *bla*<sub>KPC-2</sub>

784 region. An intramolecular replicative transposition in trans inversed the segment between

785 the 81th bp site on the  $\Delta$ Tn2 *tnpA* gene and an IS26 and duplicated an IS26 in opposite

786 orientation (precursor 2). Intramolecular replicative translocation in *cis* created a

787 translocatable unit (TU). The TU inserted into precursor 2 by conservative targeted

788 transposition to form pSRRSH1002-KPC. pSRRSH1002-KPC excised TU containing the  
789 repeated genetic segments and the  $\Delta Tn2$  *tnpA* gene to form pSRRSH1101. Another  
790 plasmid precursor 3 excised a TU containing a *bla*<sub>KPC-2</sub> gene by intramolecular replicative  
791 translocation in *cis* to form pSRRSH1408-KPC.

792

793 **Figure 4. pWTJH12-KPC plasmid structure and gene synteny.** The innermost layer  
794 indicates gene synteny of Type 2 plasmids. The second ring represent GC skew, where  
795 yellow means skew to A and T and blue means skew to G and C. The third ring represents  
796 GC content, where light-green represent GC% greater than the median and dark-pink  
797 represents GC% less than the median (sliding window of 2000 bp). The forth ring shows  
798 backbone (grey) and accessory region (black) of the plasmid. The arrows in outermost  
799 ring indicates genes on pWTJH12-KPC, which are in accordant with points of the gene  
800 synteny layers. PRTRC: ParB-related ThiF-related cassette; SAM: *S*-adenosylmethionine;  
801 T2SS: Type II secretion system.

802









803 **Figure 5. Alignment of IS6100- $\Delta Tn6296$ -Tn1403 structure from multiple strains.** Arrows  
804 denoted to genes or truncated genes. Alignment identity ranges from 99% to 100%.  
805 GenBank accession: p14057-KPC(KY296095), pNK546a (MN433457).


806

807 **Figure 6. Statistical analysis of the correlation between *bla*<sub>KPC-2</sub> gene and CAZ-AVI MIC. A.**  
808 *bla*<sub>KPC-2</sub> gene copy number comparison among strains (n=149) with different CAZ-AVI  
809 MIC groups. The asterisks, \*, \*\*, \*\*\*, represent adjusted p-values of Dunn test less than





810 0.05, 0.01, 0.001, respectively. Two strains containing metallo- $\beta$ -lactamase are not  
811 involved. **B.** *bla*<sub>KPC-2</sub> gene copy number comparison among ST463 strains (n=100) with  
812 different CAZ-AVI MIC groups. The asterisk, \*\*, represents adjusted p-values of Dunn test  
813 less than 0.01. **C.** Correlation between *bla*<sub>KPC-2</sub> gene copy number and plasmid copy  
814 number in strains containing Type 1 or Type 2 plasmid (n=134). **D.** Correlation between  
815 *bla*<sub>KPC-2</sub> gene copy number and plasmid copy number in ST463 strains containing Type 1  
816 plasmid (n=100). Each solid line indicates that points near it exhibit a *bla*<sub>KPC-2</sub> gene to  
817 plasmid copy number ratio as the slope (r). The red dashed line with a slope of 1.5  
818 distinguishes single and multiple *bla*<sub>KPC-2</sub> gene copies per plasmid. **E.** The CAZ-AVI MIC  
819 distributions of strains (n=134) containing single *bla*<sub>KPC-2</sub> gene or multiple *bla*<sub>KPC-2</sub> gene  
820 copies per plasmid. Both types of plasmids are included. **F.** The CAZ-AVI MIC  
821 distributions of strains (n=100) containing single *bla*<sub>KPC-2</sub> gene or multiple *bla*<sub>KPC-2</sub> gene  
822 copies per Type 1 plasmid. Blue and red bars represent the Single and the Multi group,  
823 respectively.  
824







- ST234
  - ST244
  - ST463
  - ST485
  - ST606
  - ST1076
  - ST1212
  - ST1631
  - ST3217
  - ST3503
  - ST3504
  - ST undefined
- plasmid types
- Type 1
  - ▲ Type 2
  - ◆ Type 1 & 2
  - ⊠ unknown



A



C



B

